Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024, with demand rising rapidly. ... Competition Heating Up in Obesity Space.

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Novo Nordisk is facing fierce competition from obesity rival Zepbound, ... where Novo’s GLP-1 products hold a 70% market share. Diabetes med Ozempic leads the charge with 47% of that.

Now, it’s worth noting Stock Advisor ’s total average return is 998 % — a market-crushing outperformance compared to 174 % for the S&P 500. Don’t miss out on the latest top 10 list ...

Zepbound brought in $2.3 billion in U.S. sales during this year’s first quarter, ... Those could hit the market in the next year or so, ... She says competition like this, ...